Results 31 to 40 of about 4,931,245 (245)

Risperidone induced tardive dyskinesia [PDF]

, 2021
Risperidone is an atypical antipsychotic drug which has been less likely to produce extrapyramidal symptoms. The aim of this case report is to illustrate that low dose risperidone may cause tardive dyskinesia.
Harichandran, Dhanya Thirookaran, Balakrishnan, Sujatha Mangattuvalappil, Kolanchinathan, Elakkya   +2 more
core   +1 more source

Drug-Induced Movement Disorders and Its Associated Factors Among Patients Attending Treatment at Public Hospitals in Eastern Ethiopia

Neuropsychiatric Disease and Treatment, 2020
Tadesse Misgana,1 Niguse Yigzaw,2 Getachew Asfaw3 1Department of Psychiatry, College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia; 2Department of Psychiatry, College of Medicine and Health Science, University of Gondar, Gondar ...
Misgana T, Yigzaw N, Asfaw G
doaj  

Clinical Management of Drug Induced Dyskinesia in Parkinson's Disease: Why Current Approaches May Need to Be Changed to Optimise Quality of Life [PDF]

European Medical Journal, 2016
Parkinson’s disease is a complex, progressive neurodegenerative disorder associated with both motor and non-motor symptoms. Current treatment strategies mainly target the alleviation of motor symptoms through dopaminergic replacement therapy.
Jean-Francois Daneault, Gloria Vergara-Diaz, Sunghoon Ivan Lee   +2 more
doaj  

Disminución de las discinesias en un modelo de Parkinson en ratas Wistar, mediada por el fitofármaco Mucuna pruriens

Neurology Perspectives, 2021
Resumen: La enfermedad de Parkinson (EP) es una enfermedad neurodegenerativa cuyo tratamiento sintomático más eficaz es la L-dopa, sin embargo, puede inducir discinesias (DIL).
J.C. Guzman, C.A. Otalora, P. Caro, E.L. Mayorga, J.P. Alcazar, L.F. Turner   +5 more
doaj   +1 more source

A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys

Neurobiology of Disease, 2010
L-DOPA remains the gold-standard treatment for Parkinson's disease but causes motor fluctuations and dyskinesia. Metabotropic glutamate receptor type 5 (mGluR5) has been proposed as a target for antidyskinetic therapies.
Daniella Rylander, Hanna Iderberg, Qin Li, Andrzej Dekundy, Jinlan Zhang, Hao Li, Ren Baishen, Wojciech Danysz, Erwan Bezard, M. Angela Cenci   +9 more
doaj   +1 more source

A Novel KCNA1 Variant in a Patient With Tremor and Autism Spectrum Disorder Causes Mixed LOF/GOF Defects of Kv1.1 Channels

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Variants in KCNA1, encoding the Kv1.1 potassium channel, cause neurological disorders including episodic ataxia and developmental and epileptic encephalopathy. We identified a novel KCNA1 variant (A401T) in a 16‐year‐old patient with autism spectrum disorder, borderline intellectual disability, and tremor, without episodic ataxia or epilepsy ...
Juan Darío Ortigoza‐Escobar, Laura Marti‐Sánchez, Loreto Martorell, Giorgia Dinoi, Antonio Vittorio Buono, Annamaria De Luca, Antonella Liantonio, Paola Imbrici   +7 more
wiley   +1 more source

Primary ciliary dyskinesia: current state of the art

, 2007
Primary ciliary dyskinesia (PCD) is usually inherited as an autosomal recessive, and in classical form presents with upper and lower respiratory tract infection, and mirror image arrangement in around 50% cases.
Hall, Pippa, Collins, Nicola F., Hariri, Mohamed, Harcourt, Jonny, Chodhari, Rahul, Lucas, Jane, Phillips, Gill, Bush, Andrew, Copeland, Fiona, Hogg, Claire, O'Callaghan, Chriatopher   +10 more
core   +1 more source

Diagnosis of drug induced liver injury using a lymphocyte blast transformation test based on whole blood culture [PDF]

, 1977
Twenty cases of suspected drug induced liver injury (16 cases of which satisfied the criteria for at least a query positive diagnosis as based on the Fourth Congress of "Drugs and the Liver" in Japan) were studied by the whole blood culture ...
Takata, Shinji
core   +1 more source

A Holistic Platform Approach for Developing Robust Pulmonary mRNA Delivery: Integrating Novel Phenolic Acid‐Derived Ionizable Lipids and Device Engineering

Advanced Functional Materials, EarlyView.
An integrated pulmonary mRNA delivery platform combining novel biodegradable syringic acid‐derived ionizable lipids, design‐of‐experiments formulation optimization, and vibrating‐mesh nebulizer engineering enabled stable aerosolization and efficient lung delivery.
Neha Kaushal, Younan Ma, Asad Khanmohammed, Dipen Parande, Hanming Zhang, Saket Dolare, Juliet Chen, Apiwat Wangweerawong, Saswata Karmakar, Hongfeng Deng, Frank Koppenhagen, Shraddha Sharma, Eric Reyes, Sherry He, Lianne Boeglin, Caroline Woo, Azadeh Paksa, Ayed Allawzi, Anusha Dias, Gregory Troiano, Shrirang Karve, Frank DeRosa   +21 more
wiley   +1 more source

Directional Deep Brain Stimulation for Parkinson's Disease: Results of an International Crossover Study With Randomized, Double‐Blind Primary Endpoint

Neuromodulation: Technology at the Neural Interface, EarlyView., 2021
Abstract Objective Published reports on directional deep brain stimulation (DBS) have been limited to small, single‐center investigations. Therapeutic window (TW) is used to describe the range of stimulation amplitudes achieving symptom relief without side effects.
Alfons Schnitzler, Pablo Mir, Matthew A. Brodsky, Leonard Verhagen, Sergiu Groppa, Ramiro Alvarez, Andrew Evans, Marta Blazquez, Sean Nagel, Julie G. Pilitsis, Monika Pötter‐Nerger, Winona Tse, Leonardo Almeida, Nestor Tomycz, Joohi Jimenez‐Shahed, Witold Libionka, Fatima Carrillo, Christian J. Hartmann, Stefan Jun Groiss, Martin Glaser, Florence Defresne, Edward Karst, Binith Cheeran, Jan Vesper, for the PROGRESS Study Investigators   +24 more
wiley   +1 more source